Abstract
Epidemics generally spread through a succession of waves that reflect factors on multiple time-scales. On short time-scales, superspreading events lead to burstiness and overdispersion, while long-term persistent heterogeneity in susceptibility is expected to lead to a reduction in the infection peak and the herd immunity threshold (HIT). Here, we develop a general approach to encompass both time-scales, including time variations in individual social activity, and demonstrate how to incorporate them phenomenologically into a wide class of epidemiological models through parameterization. We derive a non-linear dependence of the effective reproduction number Re on the susceptible population fraction S. We show that a state of transient collective immunity (TCI) emerges well below the HIT during early, high-paced stages of the epidemic. However, this is a fragile state that wanes over time due to changing levels of social activity, and so the infection peak is not an indication of herd immunity: subsequent waves can and will emerge due to behavioral changes in the population, driven (e.g.) by seasonal factors. Transient and long-term levels of heterogeneity are estimated by using empirical data from the COVID-19 epidemic as well as from real-life face-to-face contact networks. These results suggest that the hardest-hit areas, such as NYC, have achieved TCI following the first wave of the epidemic, but likely remain below the long-term HIT. Thus, in contrast to some previous claims, these reqions can still experience subsequent waves.
Significance Statement
Epidemics generally spread through a succession of waves that reflect factors on multiple time-scales. Here, we develop a general approach to encompass super-spreading and population heterogeneity, and demonstrate that a fragile state of transient collective immunity (TCI) emerges well below the HIT during early, high-paced stages of the epidemic. However, this is not an indication of herd immunity: subsequent waves can and will emerge due to behavioral changes in the population, driven (e.g.) by seasonal factors. Analysis of empirical data suggests that even in locations with strong first waves of COVID-19, subsequent waves will still emerge.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Our calculations would have been impossible without the data kindly provided by the Illinois Department of Public Health through a Data Use Agreement with Civis Analytics. This work was supported by the University of Illinois System Office, the Office of the Vice-Chancellor for Research and Innovation, the Grainger College of Engineering, and the Department of Physics at the University of Illinois at Urbana-Champaign. Z.J.W. is supported in part by the United States Department of Energy Computational Science Graduate Fellowship, provided under Award No. DE-FG02-97ER25308. This work made use of the Illinois Campus Cluster, a computing resource that is operated by the Illinois Campus Cluster Program (ICCP) in conjunction with the National Center for Supercomputing Applications (NCSA) and which is supported by funds from the University of Illinois at Urbana-Champaign. This research was partially done at, and used resources of the Center for Functional Nanomaterials, which is a U.S. DOE Office of Science Facility, at Brookhaven National Laboratory under Contract No.~DE-SC0012704.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript does not involve research on human subjects. The public data used in this study contains no identifiable private information.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Minor revisions
Data Availability
The manuscript uses data provided by the Illinois Department of Public Health through a Data Use Agreement with Civis Analytics. The source code for the model is freely available online at https://github.com/uiuc-covid19-modeling/pydemic https://github.com/uiuc-covid19-modeling/pydemic